Table 3: History of type 2 diabetes.
| Diabetes duration (y) | |
| N (%) | 201 (100) |
| Missing (%) | 0 |
| Mean (SD) | 3.1 (3.3) |
| Median | 1.78 |
| Q1; Q3 | 1.02; 4.38 |
| Range | 0.23-24.2 |
| Duration of IR metformin treatment (months) | |
| N (%) | 201 (100) |
| Missing (%) | 0 |
| Mean (SD) | 24.4 (27.9) |
| Median | 12.0 |
| Q1; Q3 | 6.0; 36.0 |
| Range | 2-180 |
| Mean daily dose of immediate release metformin pre-study mg (SD) | |
| N (%) | 201 (100) |
| Missing (%) | 0 |
| Mean (SD) | 1380 (432) |
| Median | 1500 |
| Q1; Q3 | 1000; 1700 |
| Range | 250-2000 |
| BID dosing n (%) | 196 (97.5) |
| TID dosing n (%) | 5 (2.5) |
| Duration of metformin XR treatment at baseline (weeks) | |
| N (%) | 201 (100) |
| Missing (%) | 0 |
| Mean (SD) | 21.3 (17.5) |
| Median | 14.3 |
| Q1; Q3 | 8.4; 30.4 |
| Range | 4-113.9 |
| Current dose of metformin XR (mg) | |
| N (%) | 201 (100) |
| Missing (%) | 0 |
| Mean (SD) | 1275 (447) |
| Median | 1500 |
| Q1; Q3 | 1000; 1500 |
| Range | 500-2250 |